US1873732A - Bactericide applicable to acid-fast bacteria - Google Patents

Bactericide applicable to acid-fast bacteria Download PDF

Info

Publication number
US1873732A
US1873732A US329077A US32907728A US1873732A US 1873732 A US1873732 A US 1873732A US 329077 A US329077 A US 329077A US 32907728 A US32907728 A US 32907728A US 1873732 A US1873732 A US 1873732A
Authority
US
United States
Prior art keywords
acid
applicable
bactericide
fast bacteria
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US329077A
Inventor
Adams Roger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to US329077A priority Critical patent/US1873732A/en
Application granted granted Critical
Publication of US1873732A publication Critical patent/US1873732A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126Acids containing more than four carbon atoms
    • C07C53/128Acids containing more than four carbon atoms the carboxylic group being bound to a carbon atom bound to at least two other carbon atoms, e.g. neo-acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C10PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
    • C10NINDEXING SCHEME ASSOCIATED WITH SUBCLASS C10M RELATING TO LUBRICATING COMPOSITIONS
    • C10N2040/00Specified use or application for which the lubricating composition is intended
    • C10N2040/20Metal working
    • C10N2040/24Metal working without essential removal of material, e.g. forming, gorging, drawing, pressing, stamping, rolling or extruding; Punching metal

Definitions

  • ROGER ADAMS OF URBANA, ILLINOIS, ASSIGNOR TO ABBOTT LABORATORIES, OF NORTH CHICAGO, ILLINOIS, A CORPORATION OF ILLINOIS BACTERICIDE APPLICABLE TO ACID-FAST BACTERIA No Drawing.
  • This invention relates to the preparation of aliphatic acids and derivatives of these acids.
  • These compounds have the general formula HOOOZ, R/ where R and R represent aliphatic-hydrocarbon radicals such as alkyl or alkylene, and m where Z represents a hydrogen atom, an alkali or alkaline earth metal or a hydrocarbon radical.
  • Chaulmoogra oil, chaulmoogric acid, and homologues of chaulmoogric acid and their derivatives have long been known to be effective in combating certain diseases such as leprosy, produced by acid-fast bacteria.
  • Such chaulmoogra derivatives contain an unsaturated five membered carbon ring to which the activity against the leper bacilli was formerly attributed. Recent discoveries have shown that a variety of other acids which contain other types of carbon rin are also effective against such acid-fast bac- 95 teria.
  • esters may be prepared by introducing the hydrocarbon radicals successively into an ester with an active methylene group, which then on treatment with alkalies, can yield a substituted acetic acid.
  • esters are malonic ester and acetoacetgic ester.
  • the reactions involved are as follows, where R and R are aliphatic alkyl radicals, such as alkyl or alkylene ooocim coocun 00002115 RCH/ cooo m 00001115 ROB +NaBr+CzHH.
  • the substance is administered in an equal mixture of olive oil, preferably with two per cent anesthesin, added to reduce the pain of injection, although the anesthesin is not required. That is to say, one part of the compound is mixed with an equal part of olive oil, and to this is added a quantity of anesthesin equal to two per cent of the total weight. About five to six cc. of the mixture is injected intramuscularly once a week. However, the administration can be varied substantially, both as to amount and the frequency. The quantities and method of administration of the other materials mentioned above will be similar.
  • R and R represent aliphatic hydrocarbon radicals such as alkyl or alkylene
  • Z represents a hydrogen atom, an alkali or alkaline earth metal or a hydrocarbon radical
  • R and R represent aliphatic hydrocarbon radicals such as alkyl or alkylen-e, and where Z represents a hydrogen atom, an alkyli or alkaline earth metal or a hydrocarbon radical.
  • R and R represent aliphatic hydrocarbon radicals such as alkyl or alkylene, and where Z represents a hydrogen atom, an alkali or alkyline earth metal or a hydrocarbon radical, and Where the carboxyl group is attached near the middle of the chain.
  • a new bactericidal or bacteriostatic agent especially applicable to acid-fast bacteria a substance which is a member of the group consisting of aliphatic acids, alkali and alkaline earth metal salts thereof and hydrocarbon esters thereof, in which the carboxyl group is located at a point removed from the end of the chain, said substance containing from 10 to 21 carbon atoms.
  • composition as defined in claim 4 and containing from 15 to 18 carbon atoms.
  • a new bactericidal or bacteriostatic agent especially applicable to acid-fast bacteria a substance which is a member of the group consisting of aliphatic acids, alkali and alkaline earth metal salts thereof, and
  • hydrocarbon esters thereof in which the carboxyl group is attached to a carbon atom at approximately the center of the chain, said substance containing from 10 to 21 carbon atoms.
  • ROGER ADAMS containing from 15 to 1 8 carbon atoms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

Patented-Aug. 23,; 1932- UNITED STATES PATENT m m:
ROGER ADAMS, OF URBANA, ILLINOIS, ASSIGNOR TO ABBOTT LABORATORIES, OF NORTH CHICAGO, ILLINOIS, A CORPORATION OF ILLINOIS BACTERICIDE APPLICABLE TO ACID-FAST BACTERIA No Drawing.
This invention relates to the preparation of aliphatic acids and derivatives of these acids. These compounds have the general formula HOOOZ, R/ where R and R represent aliphatic-hydrocarbon radicals such as alkyl or alkylene, and m where Z represents a hydrogen atom, an alkali or alkaline earth metal or a hydrocarbon radical. I v
Chaulmoogra oil, chaulmoogric acid, and homologues of chaulmoogric acid and their derivatives have long been known to be effective in combating certain diseases such as leprosy, produced by acid-fast bacteria.
Such chaulmoogra derivatives contain an unsaturated five membered carbon ring to which the activity against the leper bacilli was formerly attributed. Recent discoveries have shown that a variety of other acids which contain other types of carbon rin are also effective against such acid-fast bac- 95 teria.
My further discoveries seem to demonstrate that a ring structure is not necessary but that the number of carbon atoms, the molecular weight of the compounds, and the position of the carboxyl group in the chain, are the important factors in determining the bactericidal and bacteriostatic efiiciency of the products. (The term bacteriostatic means preventing growth of bacteria, as 8 distinguished from bactericidal which means bacteria destroying.) Compounds containing more than nine and less than twenty-two carbon atoms appear to be most efiicient, particularly those containing 15 to 18 carbon atoms. The presence or absence of a ring structure seems to be of minor importance.
The discovery of the bactericidal efiiciency of these acids described in this application is of particular importance since certain analogous compounds, which are very well known, such as stearic acid, show no appreciable germicidal efliciency whatsoever. In stearic acid, the carboxyl group is at the end of the chain of seventeen carbon atoms. I are prepared are given as illustrations of the 10f Application filed December 28, 1928. Serial No. 829,077.
have found that if the carboxyl group is removed from this position, and placed farther down towards the center of the chain, the efficiency is markedly increased. The highest efliciency seems to reside in such compounds in which the carboxyl group is attached to the middle carbon atom or to a .carbon atom that is near the middle.
These acids have the additional advantage that they may be prepared and made available for therapeutic use much more readily than is the case with the ring containing compounds previously studied.
These acids may be prepared by introducing the hydrocarbon radicals successively into an ester with an active methylene group, which then on treatment with alkalies, can yield a substituted acetic acid. Examples of such esters are malonic ester and acetoacetgic ester. Illustrating with malonic ester, the reactions involved are as follows, where R and R are aliphatic alkyl radicals, such as alkyl or alkylene ooocim coocun 00002115 RCH/ cooo m 00001115 ROB +NaBr+CzHH.
cooozm OOOCzHs ROB. +2NaOH- ROR ooooun ooom OOONa coon no R +2no1 ROR' +2Na01 COONa coon ROE coon heat R oooH The following examples of such acids and some of their intermediates from which they straight chains. Wherever two formulae are K invention. Unless otherwise indicated in the formula, the hydrocarbon radicals are given, the first mentioned formula refers to the intermediate diethyl dialkyl malonates.
Melting Boiling point point C4HBCH(COOH)C4HQ 153:]lfimm C4HoCH(COOCzH5) C4H 114-115 /15mm 1soC5HuCH(COOH)1so 158 15mm 146r149/2. 5mm 160162/2mm 187188/9mn1 196198/ 10mm 185186/9mm 148150/3mm 149-151/1mm 167l69/4mm 164-166/2mm 179-183/3mm 186138/1mm 175180/3mm 186-190/3mm 200204/3mm 205209/3mm As an example, ethyl di-n-heptyl acetate is representative of the group of compounds covered. by the application, which is being used clinically. The substance is administered in an equal mixture of olive oil, preferably with two per cent anesthesin, added to reduce the pain of injection, although the anesthesin is not required. That is to say, one part of the compound is mixed with an equal part of olive oil, and to this is added a quantity of anesthesin equal to two per cent of the total weight. About five to six cc. of the mixture is injected intramuscularly once a week. However, the administration can be varied substantially, both as to amount and the frequency. The quantities and method of administration of the other materials mentioned above will be similar.
The scope of the invention should be determined by reference to the appended claims, said claims being construed as broadly as possible consistent with the state of the art.
I claim as my invention:
1. As a new bactericidal or bacteriostatic agent, an aliphatic substance containing from 10 to 21 carbon atoms and having the general formula CHCOOZ, R!
where R and R represent aliphatic hydrocarbon radicals such as alkyl or alkylene, and Where Z represents a hydrogen atom, an alkali or alkaline earth metal or a hydrocarbon radical.
2. As a new bactericidal or bacteriostatic agent, an aliphatic substance containing from 15 to 18 carbon atoms and having the general formula onoooz, RI
where R and R represent aliphatic hydrocarbon radicals such as alkyl or alkylen-e, and where Z represents a hydrogen atom, an alkyli or alkaline earth metal or a hydrocarbon radical.
3. As a new bactericidal or bacteriostatic agent, an aliphatic substance containing from 10 to 21 carbon atoms and having the general formula CHCOOZ, R!
where R and R represent aliphatic hydrocarbon radicals such as alkyl or alkylene, and where Z represents a hydrogen atom, an alkali or alkyline earth metal or a hydrocarbon radical, and Where the carboxyl group is attached near the middle of the chain.
4. As a new bactericidal or bacteriostatic agent especially applicable to acid-fast bacteria, a substance which is a member of the group consisting of aliphatic acids, alkali and alkaline earth metal salts thereof and hydrocarbon esters thereof, in which the carboxyl group is located at a point removed from the end of the chain, said substance containing from 10 to 21 carbon atoms.
5. A composition as defined in claim 4, and containing from 15 to 18 carbon atoms.
6. As a new bactericidal or bacteriostatic agent especially applicable to acid-fast bacteria, a substance which is a member of the group consisting of aliphatic acids, alkali and alkaline earth metal salts thereof, and
hydrocarbon esters thereof, in which the carboxyl group is attached to a carbon atom at approximately the center of the chain, said substance containing from 10 to 21 carbon atoms.
7. A composition as defined in claim 6, and
containing from 15 to 1 8 carbon atoms. ROGER ADAMS.
US329077A 1928-12-28 1928-12-28 Bactericide applicable to acid-fast bacteria Expired - Lifetime US1873732A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US329077A US1873732A (en) 1928-12-28 1928-12-28 Bactericide applicable to acid-fast bacteria

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US329077A US1873732A (en) 1928-12-28 1928-12-28 Bactericide applicable to acid-fast bacteria

Publications (1)

Publication Number Publication Date
US1873732A true US1873732A (en) 1932-08-23

Family

ID=23283750

Family Applications (1)

Application Number Title Priority Date Filing Date
US329077A Expired - Lifetime US1873732A (en) 1928-12-28 1928-12-28 Bactericide applicable to acid-fast bacteria

Country Status (1)

Country Link
US (1) US1873732A (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2461336A (en) * 1946-04-01 1949-02-08 Standard Oil Dev Co Manufacture of glutaric acid
US2935973A (en) * 1957-02-18 1960-05-10 Du Pont Hydrocarbon fuels having improved antiknock properties
US2979455A (en) * 1958-10-03 1961-04-11 Commercial Solvents Corp Process for the control of bacteria
US3001935A (en) * 1959-05-13 1961-09-26 Commercial Solvents Corp Process for the control of bacteria in water flooding operations
US3003915A (en) * 1961-10-10 Method of destroying lactobacilli em-
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2258358A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2011063115A1 (en) 2009-11-19 2011-05-26 Braincells Inc. Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
WO2011091033A1 (en) 2010-01-20 2011-07-28 Braincells, Inc. Modulation of neurogenesis by ppar agents
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2377530A2 (en) 2005-10-21 2011-10-19 Braincells, Inc. Modulation of neurogenesis by PDE inhibition

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3003915A (en) * 1961-10-10 Method of destroying lactobacilli em-
US2461336A (en) * 1946-04-01 1949-02-08 Standard Oil Dev Co Manufacture of glutaric acid
US2935973A (en) * 1957-02-18 1960-05-10 Du Pont Hydrocarbon fuels having improved antiknock properties
US2979455A (en) * 1958-10-03 1961-04-11 Commercial Solvents Corp Process for the control of bacteria
US3001935A (en) * 1959-05-13 1961-09-26 Commercial Solvents Corp Process for the control of bacteria in water flooding operations
EP2258358A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2258359A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2258357A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2275095A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A2 (en) 2005-10-21 2011-10-19 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2382975A2 (en) 2006-05-09 2011-11-02 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011063115A1 (en) 2009-11-19 2011-05-26 Braincells Inc. Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
WO2011091033A1 (en) 2010-01-20 2011-07-28 Braincells, Inc. Modulation of neurogenesis by ppar agents

Similar Documents

Publication Publication Date Title
US1873732A (en) Bactericide applicable to acid-fast bacteria
US4980502A (en) Paramagnetic chelates
US4426371A (en) Novel N-hydroxyalkylated dicarboxylic acid bis(3,5-dicarbamoyl-2,4,6-triiodoanilides), as X-ray contrast media
EP0038192B2 (en) 5-Alkylsalicylanilides derivatives and method for inhibiting the growth of microorganisms
AU3607895A (en) 1-acyl-4-aliphatylaminopiperidine compounds
US6303101B1 (en) Bismuth compounds
IE62460B1 (en) New dicarboxylic acid-bis-(3,5-dicarbamoyl-2,4,6-triiodoanilides), process for their production as well as x-ray contrast media containing them
US6117412A (en) Non-cluster type bismuth compounds
US3655728A (en) N-(2 - dialkylaminoalkylene)-esters of fluoroalkoxy-substituted aryl carboxylic acid and salts thereof
RU95119433A (en) CRYSTAL SALTS OF ACCESSION OF CEFEME ACIDS, METHOD OF THEIR PRODUCTION, CONTAINING THEIR MEDICINE
DE1493933A1 (en) Beta (naphthyl-1) isobutyric acids and process for their preparation
US4331685A (en) Control of plant virus diseases
US3247250A (en) Carboxamido nu-substituted tetracyclines
ES8607973A1 (en) Amino-lower-alkyl-penem derivatives, process for their preparation, pharmaceutical compositions containing them and their use.
RU95107147A (en) Cyclohexanecarboxylic acid derivatives, mixture of isomers thereof or individual isomers and physiologically tolerable salts, and pharmaceutical composition having activity which inhibits enzymic glucose-phosphotase complex of liver
US3320121A (en) 2-(2',2'-dihalocyclopropyl)-1,1-dihalocyclopropane and 2,2-dihalocyclopropyl carboxylic acid as antibacterial agents
FR2369216A1 (en) WATER TREATMENT PRODUCTS CONTAINING ACYLIMINO DIACETIC ACIDS
US3051618A (en) Beta-hydroxy-butyric acid amide derivatives and process for their use as narcotics
US3719605A (en) Germicidal compound and soap compositions incorporating the same
US2941924A (en) Monoethanolamine salt of alpha-(acetylamino)-isocaproic acid
US3407234A (en) 4-(2-benzylalkylaminoalkoxy)-benzylamines
CA1251789A (en) Bis-(substituted amino) anthraquinones
DE2245467A1 (en) BENZOIC ACID DERIVATIVES
GB1187198A (en) Substituted Anilides and preparation thereof
US4124706A (en) Esters of bis-(hydroxyalkylthio)-alkanes